YTHDF1 has been shown to predict poor prognosis in glioma patients, and the knockdown of YTHDF1 in GBM inhibits proliferation and reduces resistance to temozolomide in both patient-derived cell lines and xenograft models [72,73]. The gene discussed is YTHDF1; the disease is central nervous system cancer.